Dr. Lorenz Mayr, Non-Executive Director

Dr Mayr joined FundaMental Pharma’s Board of Directors as a Non-Executive Director in March 2024.

He is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

Dr Mayr currently serves on the Board of Directors at FundaMental Pharma (Heidelberg, Germany), Phoremost (Cambridge, UK), Mogrify (Cambridge, UK), InCephalo (Basel, Switzerland), the Scientific Advisory Board of Fraunhofer IGB & IPA (Stuttgart, Germany), Fraunhofer IZI (Leipzig, Germany) and SaxoCell (Leipzig), The Francis Crick Institute (London, UK), Medicines Discovery Catapult (Alderley Park, UK), LenioBio (Düsseldorf, Germany), SensibleBio (Oxford, UK), and works as Senior Healthcare Advisor to EQT Investments (Stockholm/Sweden).

He most recently served as Chief Executive Officer of Vector BioPharma AG in Basel/Switzerland and working on novel gene delivery technologies for wide-spread applications of gene therapy and genome editing for the treatment of disease.

Dr Mayr has been working as Entrepreneur-in-Residence for Syncona Investment in London and previously as Chief Technology Officer at GE Healthcare Life Sciences, where he was responsible for R&D strategy and innovation across all life sciences business areas. He has extensive global experience in pharmaceutical R&D, including holding positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis Pharmaceuticals and Bayer Pharmaceuticals.

Dr Mayr gained his PhD at the University of Bayreuth in Biochemistry and Biophysics, subsequently completing his PostDoc at the M.I.T/Whitehead Institute in Cambridge, US.